Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab in active polyarticular JIA (GO-KIDS)
NCT01230827Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2010
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in juvenile idiopathic arthritis (JIA) comparing Golimumab with Placebo (2 arms). Primary endpoint: Percentage of Participants With American College of Rheumatology (ACR) 30 Response at Week 16 Who Did Not Experienced a Flare of Disease Through Week 48. Started Dec 2010; status: terminated.
02
Drugs
golimumab
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT01230827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01230827.